{"id":921338,"date":"2026-07-21T01:12:13","date_gmt":"2026-07-21T06:12:13","guid":{"rendered":"https:\/\/newsycanuse.com\/index.php\/2026\/07\/21\/sanofi-provides-update-on-mobilize-phase-3-study-of-riliprubart-in-chronic-inflammatory-demyelinating-polyneuropathy\/"},"modified":"2026-07-21T01:12:13","modified_gmt":"2026-07-21T06:12:13","slug":"sanofi-provides-update-on-mobilize-phase-3-study-of-riliprubart-in-chronic-inflammatory-demyelinating-polyneuropathy","status":"publish","type":"post","link":"https:\/\/newsycanuse.com\/index.php\/2026\/07\/21\/sanofi-provides-update-on-mobilize-phase-3-study-of-riliprubart-in-chronic-inflammatory-demyelinating-polyneuropathy\/","title":{"rendered":"Sanofi provides update on MOBILIZE phase 3 study of riliprubart in chronic inflammatory demyelinating polyneuropathy"},"content":{"rendered":"<p>Sanofi today announced that the riliprubart MOBILIZE phase 3 study (clinical study identifier: NCT06290128) in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) refractory to standard-of-care treatment will be stopped. This decision follows an interim analysis by an independent data monitoring committee, which determined that the MOBILIZE study is unlikely to provide sufficient efficacy&#8230;<br \/><a href=\"https:\/\/www.webwire.com\/ViewPressRel.asp?aId=356074\" class=\"button purchase\" rel=\"nofollow noopener\" target=\"_blank\">Read More<\/a><br \/>\n Dion Stoval<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sanofi today announced that the riliprubart MOBILIZE phase 3 study (clinical study identifier: NCT06290128) in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) refractory to standard-of-care treatment will be stopped. This decision follows an interim analysis by an independent data monitoring committee, which determined that the MOBILIZE study is unlikely to provide sufficient efficacy&#8230;<\/p>\n","protected":false},"author":1,"featured_media":921339,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4878,26531,192],"tags":[11903,151163],"class_list":["post-921338","post","type-post","status-publish","format-standard","has-post-thumbnail","category-provides","category-sanofi","category-sports","tag-provides","tag-sanofi"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/newsycanuse.com\/index.php\/wp-json\/wp\/v2\/posts\/921338","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/newsycanuse.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/newsycanuse.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/newsycanuse.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/newsycanuse.com\/index.php\/wp-json\/wp\/v2\/comments?post=921338"}],"version-history":[{"count":0,"href":"https:\/\/newsycanuse.com\/index.php\/wp-json\/wp\/v2\/posts\/921338\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/newsycanuse.com\/index.php\/wp-json\/wp\/v2\/media\/921339"}],"wp:attachment":[{"href":"https:\/\/newsycanuse.com\/index.php\/wp-json\/wp\/v2\/media?parent=921338"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/newsycanuse.com\/index.php\/wp-json\/wp\/v2\/categories?post=921338"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/newsycanuse.com\/index.php\/wp-json\/wp\/v2\/tags?post=921338"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}